Results 21 to 30 of about 179,392 (293)
Next Step in Chronic Kidney Disease Therapy
Počki, 2016 Angiotensin-converting enzyme inhibitors/angiotensin receptor blockers are the basis of renoprotection therapy in chronic kidney disease. Parallel to decrease of glomerular filtration rate, there is an increase in the activity of the sympathetic nervous ...
D.D. Ivanov
doaj +1 more source
Arterial Hypertension, 2022 Despite many organizational and medical efforts, the COVID-19 epidemic continues and is taking a lethal toll. Preliminary reports have already reported that the mortality associated with this disease is much higher in people with comorbidities, including
Jerzy Głuszek, Teresa Kosicka
doaj +1 more source
Angiotensin receptor blockers and risk of dementia: cohort study in UK Clinical Practice Research Datalink. [PDF]
, 2014 AIMS: This was a cohort study to evaluate whether individuals exposed to angiotensin receptor blockers have a reduced risk of dementia compared with those exposed to angiotensin-converting enzyme inhibitors.
Bhaskaran, Krishnan +5 more
core +1 more source
A krónikus szívelégtelenség epidemiológiája, a kezelési lehetőségek, a bisoprolol helye a terápiás palettán [PDF]
, 2013 The prevalence of chronic heart failure in Hungary is 1.6% in the adult population, but it occurs in 15-20% of subjects over 80 years of age. The base of treatment of heart failure is the blockade of the neuro-hormonal system, which includes the use of ...
Nagy, Viktor
core +1 more source
Angiotensin II and COVID-19. Secrets of interactions
Российский кардиологический журнал, 2020 The article describes current data on the relationship of renin-angiotensin system and related drugs with the risk of COVID-19 infection and its outcomes.
A. O. Konradi, A. O. Nedoshivin
doaj +1 more source
Comparative effectiveness of enalapril, lisinopril, and ramipril in the treatment of patients with chronic heart failure: a propensity score-matched cohort study [PDF]
, 2017 Background: Angiotensin converting enzyme inhibitors (ACEIs) are recommended as first-line therapy in patients with heart failure with reduced ejection fraction (HFrEF). The comparative effectiveness of different ACEIs is not known. Methods and results:
Agewall, Stefan +14 more
core +1 more source
Journal of Cardiac Arrhythmias, 2020 Initially reported in China at the end of 2019, the coronavirus pandemic has now reached an international scale with more than1.5 million cases worldwide and more than 80,000 deaths by April 8th of this year.
Neiberg de Alcantara Lima +4 more
doaj +1 more source
Small molecule angiotensin converting enzyme inhibitors: A medicinal chemistry perspective
Frontiers in Pharmacology, 2022 Angiotensin-converting enzyme (ACE), a zinc metalloprotein, is a central component of the renin–angiotensin system (RAS). It degrades bradykinin and other vasoactive peptides.
Wenyue Zheng +10 more
doaj +1 more source
The use of angiotensin-converting enzyme inhibitors in general medicine
South African Family Practice, 2012 Angiotensin-converting enzyme (ACE) inhibitors are a class of drugs commonly used in the management of hypertension, congestive heart failure, cerebrovascular disease, stable coronary heart disease and diabetes-associated nephropathy.
M.L.I. Mashitisho
doaj +1 more source
SGLT2 Inhibitors for Nephrologists
European Medical Journal Nephrology, 2022 Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers are the mainstay of therapy for the prevention of progressive renal damage in diabetic and non-diabetic kidney diseases, especially glomerulonephritides.
Mufti Baleegh-ur-Raheem Mahmood +1 more
doaj +1 more source